CN106913591A - 虫草多糖神经酸复合物及其应用 - Google Patents
虫草多糖神经酸复合物及其应用 Download PDFInfo
- Publication number
- CN106913591A CN106913591A CN201710046830.1A CN201710046830A CN106913591A CN 106913591 A CN106913591 A CN 106913591A CN 201710046830 A CN201710046830 A CN 201710046830A CN 106913591 A CN106913591 A CN 106913591A
- Authority
- CN
- China
- Prior art keywords
- cordyceps sinensis
- sinensis polysaccharide
- nervonic acid
- cordyceps
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001248610 Ophiocordyceps sinensis Species 0.000 title claims abstract description 103
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 101
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 101
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 title claims abstract description 64
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 title claims abstract description 64
- -1 polysaccharide nervonic acid compound Chemical class 0.000 title claims abstract description 61
- 150000004676 glycans Chemical class 0.000 claims abstract description 43
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims abstract description 29
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 10
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 10
- 241000219226 Acer truncatum Species 0.000 claims abstract description 9
- 230000036541 health Effects 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 239000012141 concentrate Substances 0.000 claims abstract description 5
- 241000233866 Fungi Species 0.000 claims description 54
- 240000001307 Myosotis scorpioides Species 0.000 claims description 50
- 241000190633 Cordyceps Species 0.000 claims description 20
- 239000004615 ingredient Substances 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000811 xylitol Substances 0.000 claims description 9
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 9
- 229960002675 xylitol Drugs 0.000 claims description 9
- 235000010447 xylitol Nutrition 0.000 claims description 9
- 229920002774 Maltodextrin Polymers 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 8
- 229940035034 maltodextrin Drugs 0.000 claims description 8
- 241001264174 Cordyceps militaris Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 244000025254 Cannabis sativa Species 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 abstract description 7
- 235000019198 oils Nutrition 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 208000004930 Fatty Liver Diseases 0.000 abstract description 2
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 2
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 230000003750 conditioning effect Effects 0.000 abstract description 2
- 208000010706 fatty liver disease Diseases 0.000 abstract description 2
- 230000006386 memory function Effects 0.000 abstract description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 235000009508 confectionery Nutrition 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 241000208140 Acer Species 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000009412 basement excavation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000024241 parasitism Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 244000283482 Alloteropsis cimicina Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000017898 Digitaria ciliaris Nutrition 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000005493 condensed matter Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了虫草多糖神经酸复合物,包括以下重量比的成分:虫草多糖,25%~85%,神经酸,3%~5%,大豆卵磷脂,10%~35%,余量为医用或食品保健用辅料,其中所述神经酸来源于元宝枫籽油。本发明的虫草多糖神经酸复合物在神经酸康复神经的同时、虫草多糖复合物提高免疫,调理血压、血脂再配以大豆磷脂,气味柔和。既可溶于油又可溶于水,具有水油兼溶性。可减少体内的胆固醇和脂肪量;改善记忆功能;有效集中精力;防止脂肪肝形成;提供多聚不饱和脂肪酸。
Description
技术领域
本发明涉及一种虫草多糖神经酸复合物和应用。
背景技术
冬虫夏草又名虫草,是我国民间惯用的一种名贵滋补药材,其营养成分高于人参,可入药,也可食用,是上乘的佳肴,具有很高的营养价值。冬虫夏草可以增强机体的免疫力,滋补肺肾,对肺癌、肝癌等有明显的抑制作用。在临床上对肺虚久咳,气喘,肺结核咯血,盗汗,肾虚腰膝酸痛,阳痿遗精,神经衰弱及化疗、放疗后的红细胞下降都有疗效。
然而原生虫草天然虫草资源稀少,目前处于限制采挖甚至禁止采挖的状态,而且经相关部门检测原生虫草重金属砷超标。其加工也维持在传统的炖、煮汤及粉碎和压片后食用。
蛹虫草为子囊菌门,肉座目,虫草菌科、虫草属的模式种,又名北冬虫夏草、北虫草等。蛹虫草目前已实现人工栽培。虫草素、虫草酸和虫草多糖是冬虫夏草菌特有的物质,是冬虫夏草特殊功效的主要指标。而恰恰是这些指标,在人工环境优裕条件下生长的北冬虫夏草含量可以比天然条件下生长得更高。人工培养的北冬虫夏草的蛋白质、氨基酸、维生素等含量均达到或超过天然冬虫夏草的水平。虽然人工培养的北冬虫夏草中的个别营养成分略低于天然冬虫夏草水平,但这些营养成分是可以通过研究加以提高的。
神经酸在元宝楓籽油中含量高达5.8%以上,元宝楓籽油中含有的神经酸是各国科学家公认的世界上唯一一个能修复受损大脑神经通路一神经纤维、并促使神经细胞再生的双效神奇物质,对常见的脑中风和老年痴呆症有显著的防治效果,除含有神经酸以外,元宝楓籽油中不饱和脂肪酸含量达95%,人体必需脂肪酸高达58%。
然而单一的虫草多糖或神经酸保健效果不具有协同作用,尚未有对其协同增效配方的形成。
发明内容
本发明针对上述问题,提出了一种虫草多糖,元宝枫籽油和大豆软磷脂的配伍,以解决了现有技术虫草和神经酸产品的缺陷,达到以虫草多糖和神经酸为主导,配以大豆软磷脂,协同增效,增强人体免疫力和提供记忆力的目的。
本发明采取的技术方案如下:
本发明提供一种虫草多糖神经酸复合物,包括以下重量比的成分:
虫草多糖,25%~42.5%,
神经酸,20%~38.5%,
大豆卵磷脂,10%~35%,
余量为医用或食品保健用辅料,
其中所述虫草多糖复合物为包括虫草多糖和虫草基础成分,其中所述虫草基础成分选自下列之一:
虫草粉或虫草发酵菌丝体的提取物或浓缩物;
其中虫草为虫草属真菌寄生并能产生子实体的菌物结合体,包括冬虫夏草,蛹虫草及虫草属的其他种;
其中所述神经酸来源于元宝枫籽油。
进一步,所述虫草多糖是利用虫草提取的多糖或者液体发酵培养虫草菌丝体,然后从发酵液中提取虫草多糖进行纯化,其中虫草为虫草属真菌寄生并能产生子实体的菌物结合体,包括冬虫夏草,蛹虫草及虫草属的其他种。
进一步,所述虫草为蛹虫草。
进一步,辅料包括木糖醇和麦芽糊精。
进一步,所述虫草多糖复合物中虫草多糖的质量分数为20%-35%。
进一步,所述虫草多糖神经酸复合物包括以下重量比的成分:虫草多糖:神经酸:大豆卵磷脂:木糖醇:麦芽糊精4:0.02:2:0.5:0.5
本发明还提供一种上述虫草多糖神经酸复合物在制备增强人体免疫力药物/食品/保健品中的应用。
此外,本发明还提供一种上述虫草多糖神经酸复合物在制备增强记忆力药物/食品/保健品中的应用。
与现有技术相比,本发明的有益效果是:
本发明将虫草多糖复合物和元宝枫籽油进行配伍,在虫草所含有效成分作为配方基础,实现两者的协同效果。
在虫草所含有效成分作为配方基础,增加功效物质虫草多糖含量,使其机理作用效能倍增,同时以虫草多糖成分领军再配以已经过临床验证具有实效性的功能营养素佐方,达到针对多种病源和亚健康得到有效调理的目标。
具体的,本发明的虫草多糖复合物将虫草多糖进一步提纯,并以多糖为主导,配以对人体机理功能具有一定效能的虫草提取物质或浓缩物质(包括维生素、矿物质、粗多糖、蛋白质等营养素),并设计合适的配比,功能物质量化提高功能效果,提高临床体验者的口感舒适度,减轻相关疾病(如肿瘤、癌症放化疗的并发症)痛苦,提高康复率有直接性的意义。
虫草有效成分基础配方中加上高含量多糖的复合配方的重要价值是对人体的疾病预防、治疗、延年益寿更精准、更高效、更合理和均衡。在实践中纯粹的高含量多糖也远未达到本发明的虫草多糖复合物的效果。而纯粹的浓缩虫草有效成分,不但不经济而且其功效也远未能达到本发明目标预期。而本发明通过大量研究发现,效果达到最高阀值的是本发明所述的虫草基础有效成份(或者浓缩基础有效成份)配上高含量虫草多糖对人类疾病的预防、治疗、延年益寿达到最佳效果。
通过与虫草多糖复合物的协同作用,神经酸的特性再次放大,可通过血脑屏障。有抗物理因素、化学因素等所致的脑功能损伤的作用,能促使脑内ADP转化为ATP,使脑内代谢能量供应状况改善,促进乙酰胆碱合成并增强神经兴奋的传递,增加多巴胺的释放。具有促进脑内代谢作用。对缺血、缺氧所致的逆行性健忘有改进作用,可以增强记忆,提高学习能力。口服后很快从消化道吸收,进入血液,并透过血脑屏障到达脑和脑脊液,大脑皮层和嗅球的浓度较脑干中浓度更高。方案采用虫草的多糖成分,能从不同角度提高人体的适应力和免疫力,有效保证产品的使用效果。
本发明在神经酸康复神经的同时、虫草多糖提高免疫,调理血压、血脂再配以大豆磷脂,气味柔和。既可溶于油又可溶于水,具有水油兼溶性。可减少体内的胆固醇和脂肪量;改善记忆功能;有效集中精力;防止脂肪肝形成;提供多聚不饱和脂肪酸。使产品的口味口感,及压方成形的需要,我们加入了木糖醇及麦芽糊精,以满足产品功效的同时兼以甘味清香。
而且本发明的虫草多糖神经酸复合物易于实现大规模工业化、标准化、自动化生产,生产效率高,有效避免了传统方法中的农药污染和重金属超标问题。
具体实施方式:
下面结合具体实施例,对本发明做详细描述。
实施例1
虫草多糖神经酸复合物
虫草多糖复合物
取虫草菌丝体,液态发酵法进行培养,培养5天后,提取培养物中的虫草多糖,提取方法采用现有技术即可,得到虫草粗多糖。
具体的,本实施例中将虫草液体发酵液在90℃~95℃的条件下,采用热水提取法浸提,将浸提液经浓缩后,用95%乙醇做沉淀剂,浓缩液和乙醇混合,将沉淀物离心后,经真空冷冻干燥,得到粗多糖;或将子实体干燥样品磨碎,索氏抽提后,抽提液加活性炭脱色,过滤,80℃水浴浓缩后,加乙醇配置成80%乙醇液,冰箱静置,过滤,洗涤。将沉淀溶解于80℃水中,然后冷却,再采用Sevag法反复去蛋白,于水浴上挥发去有机相,冷却,定容后得到多糖产品。将菌丝体粗产品在沸水中煮沸2h,离心过滤后,取上清液浓缩,加4倍体积的无水乙醇沉淀,将沉淀悬浮在水中,透析,再冷冻干燥即为粗多糖。
然后对虫草粗多糖进行提纯,获得纯度大于30%的虫草多糖。
取虫草菌丝体,液态发酵法进行培养,培养5天后,将培养物浓缩5倍,得到虫草基础成分。
按以下质量分数配置虫草多糖复合物:
虫草粗多糖18%,虫草基础成分82%,得到虫草多糖复合物。
从元宝枫籽油中提取神经酸,提取方法采用现有技术即可,得到神经算粗品,然后对其进行提纯,获得纯度大于80%的神经酸。
按以下质量分数配置虫草多糖神经酸复合物:
虫草多糖复合物,35%,神经酸,3%,大豆卵磷脂25%,木糖醇8%,麦芽糊精7%,到虫草多糖神经酸复合物。
实验证明,同等条件下,本实施例的虫草多糖神经酸复合物的疗效远超单独的神经酸。
实施例2
虫草多糖神经酸复合物
虫草多糖复合物
取虫草菌丝体,液态发酵法进行培养,培养6天后,提取培养物中的虫草多糖,提取方法采用现有技术即可,得到虫草粗多糖。然后对虫草粗多糖进行提纯,获得纯度约为45%的虫草多糖。
取虫草菌丝体,液态发酵法进行培养,培养5天后,将培养物浓缩8倍,得到虫草基础成分。
按以下质量分数配置虫草多糖复合物:
虫草多糖25%,虫草基础成分75%,得到虫草多糖复合物。
从元宝枫籽油中提取神经酸,提取方法采用现有技术即可,得到神经算粗品,然后对其进行提纯,获得纯度大于90%的神经酸。
按以下质量分数配置虫草多糖神经酸复合物:
虫草多糖,25%,神经酸,0.03%,大豆卵磷脂35%,木糖醇10%,麦芽糊精10%,到虫草多糖神经酸复合物。
实验证明,同等条件下,本实施例的虫草多糖神经酸复合物的疗效远超单独的神经酸。
实施例3
虫草多糖神经酸复合物
虫草多糖复合物
取蛹虫草菌丝体,液态发酵法进行培养,培养8天后,提取培养物中的虫草多糖,提取方法采用现有技术即可。本实施例选择用水提法提取冬虫夏草粉,得到虫草粗多糖。然后对虫草粗多糖进行提纯,获得纯度大于50%的虫草多糖。
取蛹虫草菌丝体,液态发酵法进行培养,培养5天后,将培养物浓缩15倍,得到虫草基础成分。
按以下质量分数配置虫草多糖复合物:
虫草多糖30%,虫草基础成分70%,得到虫草多糖复合物。
从元宝枫籽油中提取神经酸,提取方法采用现有技术即可,得到神经算粗品,然后对其进行提纯,获得纯度大于95%的神经酸。
按以下质量分数配置虫草多糖神经酸复合物:
虫草多糖,40%,神经酸,4%,大豆卵磷脂20%,木糖醇3%,麦芽糊精2%,到虫草多糖神经酸复合物。配制后压片制成片剂。
实验证明,同等条件下,本实施例的虫草多糖神经酸复合物的疗效远超单独的虫草多糖和单独的虫草基础成分。
实施例4
虫草多糖神经酸复合物
取蛹虫草菌丝体,液态发酵法进行培养,培养10天后,提取培养物中的虫草多糖,提取方法采用现有技术即可。本实施例选择用水提法提取冬虫夏草粉,得到虫草粗多糖。然后对虫草粗多糖进行提纯,获得纯度大于90%的虫草多糖。
取蛹虫草菌丝体,液态发酵法进行培养,培养5天后,将培养物浓缩10倍,得到虫草基础成分。
按以下质量分数配置虫草多糖复合物:
虫草多糖33%,虫草基础成分67%,得到虫草多糖复合物。
从元宝枫籽油中提取神经酸,提取方法采用现有技术即可,得到神经算粗品,然后对其进行提纯,获得纯度大于98%的神经酸。
按以下质量分数配置虫草多糖神经酸复合物:
虫草多糖,40%,神经酸,5%,大豆卵磷脂20%,木糖醇5%,麦芽糊精5%,到虫草多糖神经酸复合物。配制后压片制成片剂。
实验证明,同等条件下,本实施例的虫草多糖神经酸复合物的疗效远超单独的虫草多糖和单独的虫草基础成分。
以上所述仅为本发明的优选实施例,并非因此即限制本发明的专利保护范围,凡是运用本发明说明书内容所作的等效结构变换,直接或间接运用在其他相关的技术领域,均同理包括在本发明的保护范围内。
Claims (8)
1.虫草多糖神经酸复合物,其特征在于,所述虫草多糖神经酸复合物包括以下重量比的成分:
虫草多糖复合物,25%~85%,
神经酸,3%~5%,
大豆卵磷脂,10%~35%,
余量为医用或食品保健用辅料,
其中所述虫草多糖复合物为包括虫草多糖和虫草基础成分,其中所述虫草基础成分选自下列之一:
虫草粉或虫草发酵菌丝体的提取物或浓缩物;
其中虫草为虫草属真菌寄生并能产生子实体的菌物结合体,包括冬虫夏草,蛹虫草及虫草属的其他种;
所述神经酸来源于元宝枫籽油。
2.如权利要求1所述的虫草多糖神经酸复合物,其特征在于,所述虫草多糖是利用虫草提取的多糖或者液体发酵培养虫草菌丝体,然后从发酵液中提取虫草多糖进行纯化,其中虫草为虫草属真菌寄生并能产生子实体的菌物结合体,包括冬虫夏草,蛹虫草及虫草属的其他种。
3.如权利要求2所述的虫草多糖神经酸复合物,其特征在于,所述虫草为蛹虫草。
4.如权利要求1所述的虫草多糖神经酸复合物,其特征在于,辅料包括木糖醇和麦芽糊精。
5.如权利要求1所述的虫草多糖神经酸复合物,其特征在于,所述虫草多糖复合物中虫草多糖的质量分数为20%-35%。
6.如权利要求1所述的虫草多糖神经酸复合物,其特征在于,所述虫草多糖神经酸复合物包括以下重量比的成分:虫草多糖复合物:神经酸:大豆卵磷脂:木糖醇:麦芽糊精4:0.02:2:0.5:0.5。
7.一种如权利要求1-6任意一项所述的虫草多糖神经酸复合物在制备增强人体免疫力药物/食品/保健品中的应用。
8.一种如权利要求1-6任意一项所述的虫草多糖神经酸复合物在制备增强记忆力药物/食品/保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710046830.1A CN106913591A (zh) | 2017-01-22 | 2017-01-22 | 虫草多糖神经酸复合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710046830.1A CN106913591A (zh) | 2017-01-22 | 2017-01-22 | 虫草多糖神经酸复合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106913591A true CN106913591A (zh) | 2017-07-04 |
Family
ID=59453543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710046830.1A Pending CN106913591A (zh) | 2017-01-22 | 2017-01-22 | 虫草多糖神经酸复合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106913591A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104397706A (zh) * | 2014-12-11 | 2015-03-11 | 福州乾正药业有限公司 | 含有神经酸和磷脂类化合物的组合物及其制备方法和应用 |
-
2017
- 2017-01-22 CN CN201710046830.1A patent/CN106913591A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104397706A (zh) * | 2014-12-11 | 2015-03-11 | 福州乾正药业有限公司 | 含有神经酸和磷脂类化合物的组合物及其制备方法和应用 |
Non-Patent Citations (1)
Title |
---|
马素好,等: "虫草多糖对反复脑缺血再灌注模型小鼠记忆及脑组织SOD、MDA的影响", 《中医学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106912953A (zh) | 虫草多糖复合物及其应用 | |
CN106913854A (zh) | 虫草多糖蛋白肽复合物及其应用 | |
CN108144040A (zh) | 补肾生精的虫草牡蛎肽复合物 | |
CN104585733B (zh) | 虫草口服片剂及其制备方法 | |
CN108210878A (zh) | 补肾生精的虫草雪莲多糖复合物 | |
CN103689152B (zh) | 一种补肾清肝凉茶及其制备方法 | |
CN107811252A (zh) | 一种保健蜂蜜及其制备方法 | |
CN105192807A (zh) | 一种铁皮石斛饮料及其生产方法 | |
CN110897147A (zh) | 铁皮石斛解酒保肝组合物和制法 | |
CN101703296B (zh) | 一种榆黄蘑饮料及其制备方法 | |
CN109452634A (zh) | 真菌共生发酵降血糖辣木及其制备方法 | |
CN109043105A (zh) | 补肾生精的虫草海参肽压片糖果 | |
EP2842433B1 (en) | Food for nutritional therapy of aids | |
CN104352542A (zh) | 一种海参雪莲的组合物制剂及其制备方法 | |
CN1218745C (zh) | 一种保肝护肝及调节血脂的保健食品及其制备方法 | |
CN108148715A (zh) | 虫草多糖酒 | |
CN106913591A (zh) | 虫草多糖神经酸复合物及其应用 | |
CN104206580B (zh) | 一种莞香花叶茶饮料及其制作工艺 | |
CN106107974A (zh) | 一种红枣、枸杞、虫草组合菌丝块 | |
CN108450723A (zh) | 一种蛹虫草抗疲劳饮料及其制备方法 | |
CN106036330A (zh) | 一种以枸杞和红枣汁为载体的灵芝液体菌种转化饮品 | |
CN106107943A (zh) | 以红枣和枸杞为培养基制备桑黄菌丝块 | |
CN106071573A (zh) | 一种以枸杞和红枣汁为载体的桑黄液体菌种转化饮品 | |
CN1163729A (zh) | 天然竹汁制品及其制作方法 | |
KR20160115628A (ko) | 이엠발효 기능성 커피 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170704 |